tradingkey.logo

CVRx Inc

CVRX
View Detailed Chart

7.170USD

0.000
Close 09/19, 16:00ETQuotes delayed by 15 min
187.47MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-8.89%

1 Month

-1.10%

6 Months

-41.13%

Year to Date

-43.41%

1 Year

-22.49%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
89 / 207
Overall Ranking
198 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
11.600
Target Price
+61.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 128.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 51.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 44.75.
Overvalued
The company’s latest PE is -3.48, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 19.50M shares, decreasing 11.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.08M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Ticker SymbolCVRX
CompanyCVRx Inc
CEOMr. Kevin Hykes
Websitehttps://www.cvrx.com/
KeyAI